Search Article Keyword:  

PubMed Submission Abstract PDF Feed Back Count: 5343 Download Count: 1655 

ISSN 1007-9327 CN 14-1219/R  World J Gastroenterol  2008 January 21; 14(3): 401-407
               TOPIC HIGHLIGHT
Role of the intestinal barrier in inflammatory bowel disease

Mike G Laukoetter, Porfirio Nava, Asma Nusrat

Mike G Laukoetter, Porfirio Nava, Asma Nusrat, Epithelial Pathobiology Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, United States

Mike G Laukoetter, Department of General Surgery, University of Muenster, Muenster 48149, Germany

Supported by Grants from the German Research Foundation (Deutsche Forschungsgemeinschaft La 2359/1-1 to M.L.), National Institutes of Health (DK 55679, DK 59888 to A.N.) and Crohn’s and Colitis Foundation of America (to A.N.)

Correspondence to: Asma Nusrat, Department of Pathology and Laboratory Medicine, Emory University, Whitehead Research Building, Room 105E, 615 Michael Street, Atlanta, GA 30322, United States.

Telephone: +1-404-7278543   Fax: +1-404-7273321

Received: May 17, 2007         Revised: July 10, 2007



A critical function of the intestinal mucosa is to form a barrier that separates luminal contents from the interstitium. The single layer of intestinal epithelial cells (IECs) serves as a dynamic interface between the host and its environment. Cell polarity and structural properties of the epithelium is complex and is important in the development of epithelial barrier function. Epithelial cells associate with each other via a series of intercellular junctions. The apical most intercellular junctional complex referred to as the Apical Junction Complex (AJC) is important in not only cell-cell recognition, but also in the regulation of paracellular movement of fluid and solutes. Defects in the intestinal epithelial barrier function have been observed in a number of intestinal disorders such as inflammatory bowel disease (IBD). It is now becoming evident that an aberrant epithelial barrier function plays a central role in the pathophysiology of IBD. Thus, a better understanding of the intestinal epithelial barrier structure and function in healthy and disease states such as IBD will foster new ideas for the development of therapies for such chronic disorders.


© 2008 WJG. All rights reserved.


Key words: Intestine; Barrier function; Tight Junction; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis


Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008; 14(3): 401-407  Available from: URL:  DOI:



The functioning of the gastrointestinal tract with its balanced microflora depends on the establishment and preservation of distinct compartments which are lined by a sheet of epithelial cells. The gastrointestinal epithelial lining consists of a monolayer of columnar cells that are held together by circumferential intercellular junctions to form a selectively permeable barrier to the luminal contents. Thus, the epithelium prevents unwanted solutes, microorganisms, and luminal antigens from entering the body[1,2]. Components of the intestinal mucosal barrier include luminal secretions such as mucus which is secreted on the apical surfaces of epithelial cells, followed by IECs with lipid plasma membranes, specific membrane transport systems responsible for transepithelial passage of different molecules, and the stromal compartment below the epithelial layer. The intestinal barrier has to be permeable for nutrients and macromolecules which are important for growth and development. At the same time, it has to provide an effective barrier to harmful macromolecules and microorganisms. The mechanisms that have evolved to deal with these physiological events are extremely complex. On the one hand, the structural and functional properties of the epithelium limit the amount of antigens reaching the surface of the epithelium. On the other hand, both specialized cells of the follicle-associated epithelium (M-cells) and dendritic cells sample luminal antigens that are then delivered to the cells of the mucosal immune system thereby guaranteeing permanent immunosurveillance. An intercellular junction referred to as the tight junction (TJ) is located at the apical end of the lateral intercellular space and is considered a key player that regulates paracellular movement of fluid and solutes[3]. Altered TJ structure and epithelial permeability has been observed in IBD[2]. Additionally, pathogens and bacterial toxins influence epithelial permeability by modulating TJ proteins[4-6]. Although the permeability defects could conceivably be due to the marked apoptosis that occurs during the inflammation processes, numerous studies have clearly shown that epithelial cell apoptosis alone does not account for the entire permeability deficits[7-10]. In addition, the importance of the intestinal microflora and more specifically its composition in physiological and pathophysiological processes in the human GI tract is becoming more evident. New discoveries relate to the beneficial effects of normal microflora and probiotics in preventing gastrointestinal infections[11-13]. Probiotics released by bacteria may functionally modulate the intestinal epithelial barrier of the host by different mechanisms, including the competition of whole organisms for contact with the epithelial surface as well as stabilization of the cytoskeleton and barrier function and the induction of mucin expression.

Some of the most recently available data are discussed in this review. This field is changing rapidly and it is increasingly becoming accepted that immunogenetics play an important role in the predisposition, modulation and perpetuation of IBD. The role of the intestinal environment and the enteric flora in particular appears to be of greater significance than previously thought. This complex interaction of genetic, microbial and environmental factors culminates in a sustained activation of the mucosal immune system. This is facilitated by defects in the intestinal epithelial barrier and its mucosal immune system and results in active inflammation and tissue damage. We will concentrate on the role of the intestinal barrier, its regulation and modulation in IBD.



Mucosal integrity and repair

The small and large intestine have potent mucosal defense and repair mechanisms. These mechanisms include a fast rate of cell renewal, a capable mucosal blood flow, a continuous adherent mucus layer and the presence of regulatory peptides that can stimulate repair mechanisms. The epithelial monolayer which lines the intestinal tract originates from multipotent stem cells present in the crypts[14]. Four major IECs are generated by these multipotent cells: (1) the absorptive enterocytes (reviewed in[15]), (2) the goblet cells responsible for the assembly of mucins[16] and trefoil peptides needed for epithelial growth and repair, (3) the enteroendocrine cells which export peptide hormones (reviewed in[17]) and (4) the paneth cells which secrete antimicrobial cryptidins or defensins, digestive enzymes and growth factors[18]. Injury to the epithelial lining resulting in mucosal erosion/ulceration can occur following exposure to pathogens and chemical therapeutic agents, decreased mucosal defense such as an abnormal mucus layer or reduced production of growth regulatory peptides. The GI tract epithelium has a remarkable capacity to rapidly reseal superficial erosions by migration of epithelial cells, a process referred to as restitution. Epithelial cell proliferation contributes to resealing of larger ulcers. Wound closure is influenced by a diverse array of peptides and growth factors released into the milieu of the regenerating epithelium. For example, the mucosal integrity peptide, TGFa (transforming growth factor a) directly acts on the enterocytes to stimulate proliferation and migration. TGFb, and the pancreatic secretory trypsin inhibitor (PSTI) protect the overlying mucus layer from excessive digestion by luminal proteases and are involved in maintaining normal mucosal integrity[19]. Epidermal growth factor has been proposed as mucosal protector, playing an important role in luminal surveillance and rapid response to injury[20,21]. Mucosal epithelial cells and paneth cells produce a variety of antimicrobial peptides (defensins, cathelicidins, cryptidin related sequence peptides, chemokine CCL20) and bacteriolytic enzymes (lysozyme, group A phospholipase A2) that protect mucosal surfaces and crypts containing intestinal stem cells against invading microorganisms[21-23]. Trefoil peptides found in the goblet cells of the intestine are a family of three small proteins (TFF1, 2 and 3) which bind to the membrane-anchored glycoproteins of the filamentous brush border glycocalyx of the IECs. These peptides promote cell migration and interact with mucins such as MUC2, suggesting cooperation between the two in epithelial cell protection[24] and preservation of mucosal integrity[25]. Such peptides are rapidly up-regulated at sites of injury and inflammation. Recent experimental data has shown that the physiological role of TFF2, a member of the gastrointestinal trefoil factor family is associated with modulation of the immune system[25] and that the TFF2 rhythm is impaired in cohorts of individuals known to suffer from gastric symptoms, like H pylori infection and sleep deprivation[26].




Intercellular junctions in epithelial cells play a vital role in regulating mucosal barrier properties. Specifically, the epithelial AJC consisting of the TJ and adherens junction (AJ) (Figure 1) is important in regulating cell-cell adhesion and paracellular movement of fluids and solutes. TJs are continuous, circumferential belt-like structures that form a permeability barrier at the apical end of the intercellular space. TJs regulate vectorial transport of water and electrolytes across the intestinal epithelium and prevent leakage of macromolecules from the gut lumen[27,28]. Additionally, TJs restrict the diffusion of lipids and proteins between the apical and basolateral plasma membranes (fence function) thereby preserving cellular polarity and, in combination with transcellular vectorial transport processes, generate distinct environments in the opposing compartments across the epithelium. Lastly, TJ proteins play an important role in the overall epithelial differentiation of cells, and their deregulation has been observed in epithelial cancers[29-31]. By freeze-fracture electron microscopy, TJs are viewed as a series of anastomosing intramembranous strands, the complexity of which correlates with barrier properties of the epithelium[32,33]. The TJ is a highly dynamic structure that regulates physiologic processes such as glucose absorption[3] and undergoes rapid regulatory changes in response to inflammation[34]. The AJs reside immediately subadjacent to TJs and play an important role in cell recognition and in mediating intercellular associations[35,36]. Both the TJ and AJ are intimately linked in their regulation and function and have therefore been collectively referred to as the AJC. Lastly, subadjacent to the AJC are spot-like intercellular junctions referred to as desmosomes (DMs). Although DMs create strong intercellular associations important in the integrity of stratified epithelia such as the epidermis, the function of DMs in the intestinal epithelium is poorly understood.

At a structural level, all the above intercellular junctions consist of transmembrane proteins that affiliate with the cytoskeleton via cytoplasmic plaque proteins. The association of AJC proteins with an underlying perijunctional filamentous actin (F-actin) ring plays an important structural and regulatory role in the AJC[37]. Key integral membrane proteins of the TJ include occludin, claudin family members, junction adhesion molecule-A (JAM-A) and the coxackie adenovirus receptor (CAR). These proteins are believed to interact in a heterotypic or homotypic fashion in the extracellular space to create the selectively permeable epithelial barrier[37-39]. The intracytoplasmic domains of these TJ proteins interact with scaffolding proteins like the zonula occludens proteins (ZO), which contain several protein-protein interaction domains such as the PDZ domains (PSD 95, Discs large, ZO-1) important in mediating interactions of AJC-associated proteins. E-cadherin is a major transmembrane protein in AJs that associates with the apical perijunctional F-actin ring via cytoplasmic proteins in the catenin family[28,36,40]. The intestinal epithelial intercellular junctions are not static extracellular domains. Their adaptive mechanisms can undergo rapid regulatory changes in response to inflammation processes affiliated with IBD. Moreover the appropriate function of the AJC is coordinated by a complex array of signaling proteins which include the Rho and Rap family of GTPases, kinases and phosphatases[9,10,28].



Most current treatments for IBD are aimed at reducing disease severity and at prolonging periods of disease-free remission by pharmaceutical suppression of inflam-mation. It appears that the pathophysiology of IBD is multifactorial. The enormous complexity of IBD patho-physiology therefore requires a systematic approach to identify the molecular events that cause and sustain the chronic, recurring inflammation. It has been suggested that the continuous stimulation of the mucosal immune system due to an increased permeability of the IECs may be the primary defect in patients suffering from IBD, whereas a healthy epithelium provides an effective barrier against luminal antigens. Increased paracellular permeability has been documented in the epithelial lining from both the acutely inflamed and chronically damaged areas of the intestine[41,42]. Animal studies support the tendency for development of inflammation in areas of the intestine lying beneath the permeability defect[43] or even for an increased permeability prior to the onset of a spontaneous intestinal inflammation[44]. It is well known that intestinal permeability is regulated directly through alteration of TJ proteins, or indirectly through effects on the cytoskeleton. A broad array of inflammatory cytokines have been reported to regulate TJs and barrier function by recruiting additional inflammatory cells into the intestinal wall and by re-distribution of TJ proteins in IECs and endothelial cells[45].



Besides genetic linkage like CARD15/NOD2 mutations on chromosome 16[46,47], OCTN1 and 2 mutations on chromosome 5 and DLG5 mutations on chromosome 10[48], abundant evidence indicates that increased intestinal permeability is implicated in the pathogenesis of CD[49]. The integrity of the intestinal barrier in patients with Crohn’s disease is known to be compromised. Moreover, first degree relatives of patients with CD have been documented to have increased enteric permeability[50-52]. Interestingly, spouses of patients with CD suffered from increased intestinal permeability[53], which suggests that environmental factors may play a role. It has not been investigated whether these individuals develop CD or other gastrointestinal disorders. However, the debate continues if the increased enteric permeability is to blame for the development of CD or if the barrier defect is a consequence of an existing immune or inflammatory response. Animal models mimicking CD such as the SAMP1/Yit model, showed increased paracellular permeability across intestinal epithelial cells at an early stage of disease (three week old mice), prior to the onset of inflammation[54]. Transgenic animal models revealed the importance of E-cadherin in maintaining the epithelial barrier by demonstrating that dysfunction of AJ proteins contributed to an IBD-like process[55]. In addition, a number of studies have shown a potential role for inflammatory cytokines like TNF-k and IFN-g in directly increasing intestinal epithelial permeability. In vitro model systems have demonstrated that such pro-inflammatory cytokines influence barrier function by inducing disassembly of TJs in epithelial cells[7,9,10,56]. Furthermore, a role for TNF-k in both apoptosis independent disruption of epithelial barrier function via alteration of TJs and upregulation of epithelial apoptosis (reversible by anti-TNF-k antibody treatment) in the absence of changes in the expression of TJ proteins was reported, suggesting that TNF-k may be one of the major links between the leaky bowel and Crohn’s disease[57,58]. Soderholm et al[59] reported that non-inflamed ileac mucosa from patients with CD showed increased epithelial permeability and that increased endosomal uptake of antigens in ileac CD may be mediated by TNF-k[60]. A recently published study pertaining to the expression of TJ proteins (occludin and zonula occludens), alpha2-smooth muscle actin, TGF-k with a cytoskeletal protein (F-actin) in the intestinal epithelium of patients with inflammatory bowel disease showed that latent dislocation of TJ proteins, without disturbance of the cytoskeleton in the inactive mucosa of patients with CD, may permit the invasion of gut antigens secondary to the functional disruption of TJs, that in turn could initiate an altered immune response[61]. Some reports have demonstrated that IFN-g increases permeability across model intestinal epithelial cell lines[7,56]. Recently published data suggest that normally poorly invasive enteric bacteria may, in situations of inflammatory stress, exploit lipid raft-mediated transcytotic pathways to cross the intestinal epithelium because of INF-g-induced disruption of TJs[62]. Although the mechanisms by which IFN-g induces permeability changes across the epithelium are still incompletely understood, our data demonstrated that the permeability changes occur secondary to endocytosis of TJ transmembrane proteins occludin, JAM-A and claudin-1[9]. Furthermore, we believe that such endocytosis of TJ proteins is initiated by activation of the Rho GTPases and subsequent downstream activation of Rho kinase and actin-myosin contraction[10].



UC is characterized by diffuse mucosal chronic inflam-matory disease in the colon. Analogous chronic mucosal inflammation has been observed in animal models such as the mdr1a-/- mice. In this mdr1a-/- animal model a link between epithelial barrier dysfunction and development of colitis has been proposed[63]. Moreover, UC is associated with a mutation of the Toll-like receptor (TLR)-4 gene in humans, resulting in impaired lipopolysaccharide (LPS) signaling[64]. LPS comprises the major cell wall component of gram-negative bacteria and is mainly recognized via TLR-4. Stimulation of TLR-4 with bacterial LPS or other ligands[65] leads to activation of the NF-kB signaling system and subsequent induction of inflammatory responses[66]. Kiechl et al[67] showed that carriers of these mutations displayed an increased risk of gram-negative infections stressing that the predisposition of UC is associated with a genetic background. Besides these genetic factors, it has been demonstrated that an activated mucosal immune system leads to impaired epithelial barrier function and tissue destruction in patients suffering from UC[6,68]. In contrast to patients with CD, where the cytokines IFN-g and TNF-k play a central role in altering the epithelial barrier function, it still remains unclear which panel of cytokines regulates inflammation and induces epithelial barrier dysfunction in UC. Recently published data has shown that IL-13 produced by CD1-reactive natural killer T cells (NKT) played a central role in a murine model of colitis[69]. The IL-13 producing cells were also found in patients suffering from UC which suggests that this cytokine is one of the key mediators in the intestinal pathology of UC. Interestingly Heller et al showed that IL-13 mediates a drop of transepithelial resistance without any induction of necrosis in model IECs by increasing the paracellular permeability stressing the profound effect of IL-13 on epithelial barrier function[34]. Furthermore, it has been shown that IL-13 is produced in large amounts in the lamina propria of patients with UC. This is accompanied by increased expression of the pore-forming tight junction molecule claudin 2, which leads to the development of impaired barrier function for small cations and is thought to be responsible for the diarrhea in UC[70].



Data from different in vitro and in vivo models support the involvement of luminal bacteria in mucosal inflammation and alteration of the intestinal barrier function especially in UC. In contrast to CD, ulcerative colitis is a disease involving mucosa only. Intestinal inflammation is accompanied by direct adherence of bacteria to this mucosal surface while the protective function of the mucus layer seems to be disrupted[71]. Studies have shown that bacteria like E. coli, lactobacilli, bifidobacteria and streptococci are able to interact with immunocompetent cells, using the mucosal interface and locally modulate the production of proinflammatory cytokines[72]. They may also directly change the structure of the intestinal epithelial barrier. Although the treatment of CD with probiotics has not demonstrated any sufficient results yet[73-75], the treatment of UC has shown encouraging data[76-81]. Generally the mechanisms by which probiotic microbial agents contribute to the protection of the inflamed intestinal epithelium involve two main categories: (1) competition for binding sites and inhibition of pathogen growth as well as epithelial attachment or invasion[82,83] and (2) stimulation of the mucosal immune system including the stimulation of anti-inflammatory cytokine levels and enhancement of the barrier function. Recent work provided evidence that protective effects of probiotic microorganisms in a DSS model of experimental colitis are mediated by DNA, which was recognized by the mucosal TLR9 receptor and this interaction consequently lead to an increased production of b-defensins. Defensins are known to be responsible for the destabilization and disruption of microorganism cell membranes, leading to an increase in permeability and leakage of small molecules[84,85]. To combat invading pathogens, phagocytes need to be recruited to sites of bacterial entry. Leukocyte recruitment occurs along gradients of chemotactic factors, including chemokines and defensin chemoattractants at nanomolar concentrations[86,87]. In addition, it has been shown that the probiotic compound VSL #3 was effective as primary therapy in a colitis model of IL-10 gene-deficient mice. A direct effect on epithelial barrier function was described. The treatment resulted in a normalization of colonic physiologic function and barrier integrity along with a reduction in mucosal levels of proinflammatory cytokines and a significant improvement in histological disease by secretion of soluble factors enhancing the barrier integrity[88]. This stabilization of the intestinal barrier function is an important target in the treatment of intestinal inflammatory disorders. Otte et al[89] reported that the treatment of cultured IECs with VSL #3 lead to an increase of the transepithelial electrical resistance (TEER). In addition, this probiotic mixture was found to diminish Salmonella-induced alterations in the cellular cytoskeleton[90,91], including the distribution of the tight junction protein ZO-1. The stabilization of the cytoskeleton by regulation of tight junctions is important in the preservation of the epithelial architecture and, thereby, in the maintenance of the intestinal barrier, which might be affected by the MAPK pathway as postulated by the authors[89]. Interestingly, the incubation of IECs with these probiotics also induced the expression of several mucins, leading to less adhesion of microorganisms and its compounds like LPS to the epithelial surface. Together these housekeeping mechanisms might be responsible for the homeostasis of the intestinal barrier function during inflammatory disorders like UC.



The pathophysiology of intestinal inflammation is multifactorial. Whatever the trigger, increased epithelial permeability plays a central role in the inflammatory process. The permeability changes and inflammation are intimately linked and play a central role in perpetuating the chronic mucosal damage observed in IBD. TJs do not merely represent static junctions between epithelial cells but are multifunctional protein complexes involved in numerous vital and diverse functions of epithelial cells. It is becoming evident that the TJs are extremely dynamic structures involved in developmental, physiological, and pathological conditions like CD and UC, where defects in mucosal integrity and repair remain key elements in initiation and perpetuation of the disease. Future studies will be focused on the mechanisms by which the epithelial barrier can be made “less leaky”. The mucosal immune system is the central effector of intestinal inflammation and injury, with cytokines playing a central role in modulating inflammation and epithelial barrier function. Cytokines are, therefore, logical targets for IBD therapy. Finally, preliminary clinical trials of probiotic therapies in IBD may offer a valuable tool for prevention and control of IBD. Understanding the function and action of these probiotics will lead to the selection of useful probiotic strains for clinical application. As more work is directed at the function and modulation of the intestinal barrier, further potential therapeutic targets will provide more options to combat CD and UC.



We thank Brigitte Horst for valuable comments on the manuscript.



1         Watson AJ, Chu S, Sieck L, Gerasimenko O, Bullen T, Campbell F, McKenna M, Rose T, Montrose MH. Epithelial     barrier function in vivo is sustained despite gaps in epithelial layers. Gastroenterology 2005; 129: 902-912   PubMed

2         Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest     2004; 84: 282-291   PubMed

3         Turner JR, Rill BK, Carlson SL, Carnes D, Kerner R, Mrsny RJ, Madara JL. Physiological regulation of epithelial tight     junctions is associated with myosin light-chain phosphorylation. Am J Physiol 1997; 273: C1378-C1385   PubMed

4         Berkes J, Viswanathan VK, Savkovic SD, Hecht G. Intestinal epithelial responses to enteric pathogens: effects on the     tight junction barrier, ion transport, and inflammation. Gut 2003; 52: 439-451   PubMed

5         Fasano A, Nataro JP. Intestinal epithelial tight junctions as targets for enteric bacteria-derived toxins. Adv Drug Deliv     Rev 2004; 56: 795-807   PubMed

6         Fasano A, Baudry B, Pumplin DW, Wasserman SS, Tall BD, Ketley JM, Kaper JB. Vibrio cholerae produces a second     enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA 1991; 88: 5242-5246   PubMed

7         Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A. Proinflammatory cytokines     disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003; 171: 6164-6172   PubMed

8         Madara JL. Maintenance of the macromolecular barrier at cell extrusion sites in intestinal epithelium: physiological     rearrangement of tight junctions. J Membr Biol 1990; 116: 177-184   PubMed

9         Bruewer M, Utech M, Ivanov AI, Hopkins AM, Parkos CA, Nusrat A. Interferon-gamma induces internalization of     epithelial tight junction proteins via a macropinocytosis-like process. FASEB J 2005; 19: 923-933   PubMed

10      Utech M, Ivanov AI, Samarin SN, Bruewer M, Turner JR, Mrsny RJ, Parkos CA, Nusrat A. Mechanism of IFN-gamma-   induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane.     Mol Biol Cell 2005; 16: 5040-5052   PubMed

11      Besselink MG, Timmerman HM, van Minnen LP, Akkermans LM, Gooszen HG. Prevention of infectious complications in    surgical patients: potential role of probiotics. Dig Surg 2005; 22: 234-244   PubMed

12      Nava GM, Bielke LR, Callaway TR, Castaneda MP. Probiotic alternatives to reduce gastrointestinal infections: the    poultry experience. Anim Health Res Rev 2005; 6: 105-118   PubMed

13      Nava GM, Castaneda MP, Juarez MA. Effective probiotic therapy. Clin Nutr 2005; 24: 478   PubMed

14      Pinto D, Clevers H. Wnt control of stem cells and differentiation in the intestinal epithelium. Exp Cell Res 2005; 306:    357-363   PubMed

15      Bjerknes M, Cheng H. Gastrointestinal stem cells. II. Intestinal stem cells. Am J Physiol Gastrointest Liver Physiol 2005;    289: G381-G387   PubMed

16      Shaoul R, Okada Y, Cutz E, Marcon MA. Colonic expression of MUC2, MUC5AC, and TFF1 in inflammatory bowel    disease in children. J Pediatr Gastroenterol Nutr 2004; 38: 488-493   PubMed

17      Strader AD, Woods SC. Gastrointestinal hormones and food intake. Gastroenterology 2005; 128: 175-191   PubMed

18      Wehkamp J, Fellermann K, Stange EF. Human defensins in Crohn's disease. Chem Immunol Allergy 2005; 86: 42-54


19      Dignass AU, Sturm A. Peptide growth factors in the intestine. Eur J Gastroenterol Hepatol 2001; 13: 763-770      PubMed

20      Playford RJ. Peptides and gastrointestinal mucosal integrity. Gut 1995; 37: 595-597   PubMed

21      Muller CA, Autenrieth IB, Peschel A. Innate defenses of the intestinal epithelial barrier. Cell Mol Life Sci 2005; 62:    1297-1307   PubMed

22      Schauber J, Rieger D, Weiler F, Wehkamp J, Eck M, Fellermann K, Scheppach W, Gallo RL, Stange EF. Heterogeneous    expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2006; 18:    615-621   PubMed

23      Kelly P, Bajaj-Elliott M, Katubulushi M, Zulu I, Poulsom R, Feldman RA, Bevins CL, Dhaliwal W. Reduced gene    expression of intestinal alpha-defensins predicts diarrhea in a cohort of African adults. J Infect Dis 2006; 193: 1464-   1470   PubMed

24      Wright NA. Interaction of trefoil family factors with mucins: clues to their mechanism of action? Gut 2001; 48: 293-   294   PubMed

25      Baus-Loncar M, Schmid J, Lalani el-N, Rosewell I, Goodlad RA, Stamp GW, Blin N, Kayademir T. Trefoil factor 2(TFF2)   deficiency in murine digestive tract influences the immune system. Cell Physiol Biochem 2005; 16: 31-42   PubMed

26      Johns CE, Newton JL, Westley BR, May FE. The diurnal rhythm of the cytoprotective human trefoil protein TFF2 is    reduced by factors associated with gastric mucosal damage: ageing, Helicobacter pylori infection, and sleep    deprivation. Am J Gastroenterol 2005; 100: 1491-1497   PubMed

27      Nusrat A, Parkos CA, Verkade P, Foley CS, Liang TW, Innis-Whitehouse W, Eastburn KK, Madara JL. Tight junctions    are membrane microdomains. J Cell Sci 2000; 113: 1771-1781   PubMed

28      Ivanov AI, Nusrat A, Parkos CA. Endocytosis of the apical junctional complex: mechanisms and possible roles in    regulation of epithelial barriers. Bioessays 2005; 27: 356-365   PubMed

29      Wang Z, Mandell KJ, Parkos CA, Mrsny RJ, Nusrat A. The second loop of occludin is required for suppression of Raf1-   induced tumor growth. Oncogene 2005; 24: 4412-4420   PubMed

30      Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T. Tight junction protein claudin-1 enhances the invasive activity of oral    squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-   2 and membrane-type MMP-1. Cancer Res 2006; 66: 5251-5257   PubMed

31      Usami Y, Chiba H, Nakayama F, Ueda J, Matsuda Y, Sawada N, Komori T, Ito A, Yokozaki H. Reduced expression of    claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Hum Pathol 2006; 37:    569-577   PubMed

32      McCarthy KM, Skare IB, Stankewich MC, Furuse M, Tsukita S, Rogers RA, Lynch RD, Schneeberger EE. Occludin is a    functional component of the tight junction. J Cell Sci 1996; 109: 2287-2298   PubMed

33      Fujimoto K. Freeze-fracture replica electron microscopy combined with SDS digestion for cytochemical labeling of    integral membrane proteins. Application to the immunogold labeling of intercellular junctional complexes. J Cell Sci    1995; 108: 3443-3449   PubMed

34      Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, Burgel N, Fromm M, Zeitz M,    Fuss I, Strober W, Schulzke JD. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial    tight junctions, apoptosis, and cell restitution. Gastroenterology 2005; 129: 550-564   PubMed

35      Vestweber D, Kemler R. Some structural and functional aspects of the cell adhesion molecule uvomorulin. Cell Differ    1984; 15: 269-273   PubMed

36      Gumbiner B, Stevenson B, Grimaldi A. The role of the cell adhesion molecule uvomorulin in the formation and    maintenance of the epithelial junctional complex. J Cell Biol 1988; 107: 1575-1587   PubMed

37      Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol 2003; 81: 1-44


38      Balda MS, Gonzalez-Mariscal L, Matter K, Cereijido M, Anderson JM. Assembly of the tight junction: the role of    diacylglycerol. J Cell Biol 1993; 123: 293-302   PubMed

39      Benais-Pont G, Punn A, Flores-Maldonado C, Eckert J, Raposo G, Fleming TP, Cereijido M, Balda MS, Matter K.    Identification of a tight junction-associated guanine nucleotide exchange factor that activates Rho and regulates    paracellular permeability. J Cell Biol 2003; 160: 729-740   PubMed

40      Gumbiner BM, McCrea PD. Catenins as mediators of the cytoplasmic functions of cadherins. J Cell Sci Suppl 1993; 17:    155-158   PubMed

41      Meddings JB, Sutherland LR, May GR. Intestinal permeability in patients with Crohn's disease. Gut 1994; 35: 1675-   1676   PubMed

42      Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss HD, Bentzel CJ, Riecken EO, Schulzke JD. Altered tight junction    structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 1999; 116: 301-   309   PubMed

43      Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3:    521-533   PubMed

44      Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, Fedorak RN. Interleukin-10 gene-deficient mice develop a primary    intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 1999; 5: 262-270   PubMed

45      Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease:    relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 2005; 17: 547-557   PubMed

46      Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Abbott WG, Krissansen GW. Polymorphisms of CARD15/NOD2 and    CD14 genes in New Zealand Crohn's disease patients. Immunol Cell Biol 2005; 83: 498-503   PubMed

47      Nagy Z, Karadi O, Rumi G, Rumi G Jr, Par A, Mozsik G, Czirjak L, Suto G. Crohn's disease is associated with    polymorphism of CARD15/NOD2 gene in a Hungarian population. Ann N Y Acad Sci 2005; 1051: 45-51   PubMed

48      Vermeire S, Rutgeerts P. Current status of genetics research in inflammatory bowel disease. Genes Immun 2005; 6:    637-645   PubMed

49      Gibson PR. Increased gut permeability in Crohn's disease: is TNF the link? Gut 2004; 53: 1724-1725   PubMed

50      May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with    Crohn's disease? Gastroenterology 1993; 104: 1627-1632   PubMed

51      Soderholm JD, Olaison G, Lindberg E, Hannestad U, Vindels A, Tysk C, Jarnerot G, Sjodahl R. Different intestinal    permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal    defence? Gut 1999; 44: 96-100   PubMed

52      Thjodleifsson B, Sigthorsson G, Cariglia N, Reynisdottir I, Gudbjartsson DF, Kristjansson K, Meddings JB, Gudnason V,    Wandall JH, Andersen LP, Sherwood R, Kjeld M, Oddsson E, Gudjonsson H, Bjarnason I. Subclinical intestinal    inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003; 124: 1728-1737   PubMed

53      Breslin NP, Nash C, Hilsden RJ, Hershfield NB, Price LM, Meddings JB, Sutherland LR. Intestinal permeability is    increased in a proportion of spouses of patients with Crohn's disease. Am J Gastroenterol 2001; 96: 2934-2938      PubMed

54      Olson TS, Reuter BK, Scott KG, Morris MA, Wang XM, Hancock LN, Burcin TL, Cohn SM, Ernst PB, Cominelli F, Meddings    JB, Ley K, Pizarro TT. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med    2006; 203: 541-552   PubMed

55      Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-   cadherin. Science 1995; 270: 1203-1207   PubMed

56      Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-   alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression.    Am J Pathol 2005; 166: 409-419   PubMed

57      Brown SJ, Abreu MT. Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease. Curr Opin Drug    Discov Devel 2005; 8: 160-168   PubMed

58      Poritz LS, Garver KI, Tilberg AF, Koltun WA. Tumor necrosis factor alpha disrupts tight junction assembly. J Surg Res    2004; 116: 14-18   PubMed

59      Soderholm JD, Peterson KH, Olaison G, Franzen LE, Westrom B, Magnusson KE, Sjodahl R. Epithelial permeability to    proteins in the noninflamed ileum of Crohn's disease? Gastroenterology 1999; 117: 65-72   PubMed

60      Soderholm JD, Streutker C, Yang PC, Paterson C, Singh PK, McKay DM, Sherman PM, Croitoru K, Perdue MH.    Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor    alpha. Gut 2004; 53: 1817-1824   PubMed

61      Oshitani N, Watanabe K, Nakamura S, Fujiwara Y, Higuchi K, Arakawa T. Dislocation of tight junction proteins without    F-actin disruption in inactive Crohn's disease. Int J Mol Med 2005; 15: 407-410   PubMed

62      Clark E, Hoare C, Tanianis-Hughes J, Carlson GL, Warhurst G. Interferon gamma induces translocation of commensal    Escherichia coli across gut epithelial cells via a lipid raft-mediated process. Gastroenterology 2005; 128: 1258-1267


63      Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug    resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161: 5733-5744   PubMed

64      Torok HP, Glas J, Tonenchi L, Mussack T, Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in    inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin    Immunol 2004; 112: 85-91   PubMed

65      Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376   PubMed

66      Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation    of adaptive immunity. Nature 1997; 388: 394-397   PubMed

67      Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA. Toll-like receptor 4    polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-192   PubMed

68      Sandle GI, Higgs N, Crowe P, Marsh MN, Venkatesan S, Peters TJ. Cellular basis for defective electrolyte transport in    inflamed human colon. Gastroenterology 1990; 99: 97-105   PubMed

69      Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling    ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002; 17: 629-638   PubMed

70      Amasheh S, Meiri N, Gitter AH, Schoneberg T, Mankertz J, Schulzke JD, Fromm M. Claudin-2 expression induces    cation-selective channels in tight junctions of epithelial cells. J Cell Sci 2002; 115: 4969-4976   PubMed

71      Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S,    Dietel M, Lochs H. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54   PubMed

72      Blum S, Schiffrin EJ. Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic    bacteria? Curr Issues Intest Microbiol 2003; 4: 53-60   PubMed

73      Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig    Dis Sci 2000; 45: 1462-1464   PubMed

74      Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after    curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-409


75      Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining    remission of Crohn's disease. BMC Gastroenterol 2004; 4: 5   PubMed

76      Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C,    Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as    with standard mesalazine. Gut 2004; 53: 1617-1623   PubMed

77      Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the    composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients    with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103-1108   PubMed

78      Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-   mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-1546   PubMed

79      Gionchetti P, Amadini C, Rizzello F, Venturi A, Poggioli G, Campieri M. Probiotics for the treatment of postoperative    complications following intestinal surgery. Best Pract Res Clin Gastroenterol 2003; 17: 821-831   PubMed

80      Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA.    Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut    2004; 53: 108-114   PubMed

81      Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M.    Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;    124: 1202-1209   PubMed

82      Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in    vitro by inducing intestinal mucin gene expression. Am J Physiol 1999; 276: G941-G950   PubMed

83      Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines    and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35: 483-489   PubMed

84      Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K,    Raz E. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.    Gastroenterology 2004; 126: 520-528   PubMed

85      Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME. Interaction of human defensins with Escherichia coli.    Mechanism of bactericidal activity. J Clin Invest 1989; 84: 553-561   PubMed

86      Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-568   PubMed

87      Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127


88      Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria    enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-591   PubMed

89      Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am    J Physiol Gastrointest Liver Physiol 2004; 286: G613-G626   PubMed

90      Jepson MA, Collares-Buzato CB, Clark MA, Hirst BH, Simmons NL. Rapid disruption of epithelial barrier function by    Salmonella typhimurium is associated with structural modification of intercellular junctions. Infect Immun 1995; 63:    356-359   PubMed

91      Jepson MA, Schlecht HB, Collares-Buzato CB. Localization of dysfunctional tight junctions in Salmonella enterica    serovar typhimurium-infected epithelial layers. Infect Immun 2000; 68: 7202-7208   PubMed


S- Editor  Liu Y    L- Editor  Alpini GD    E- Editor  Li JL




Reviews Add

Related Articles:
Synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting
Non-invasive investigation of inflammatory bowel disease
Fertility and pregnancy in inflammatory bowel disease
Prevalence, predictors, and clinical consequences of medical adherence in IBD: How to improve it?
Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease